Cambridge Neuroscience Cerestat
Executive Summary
Boehringer Ingelheim dissolves collaboration to develop Cerestat (aptiganel) for the treatment of traumatic brain injury and stroke with Cambridge Neuroscience following cancellation of Phase III clinical trials begun in 1996. Cambridge said it intends to pursue development of aptiganel through a new collaboration. Outstanding issues in the dissolution include the financial terms of Cambridge's use of data generated by the two companies, Cambridge's repayment of amounts due Boehringer, and the amount Boehringer will charge Cambridge for drug inventory